[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354040-105":59,"doc-detail-354040-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mutant-and-wild-type-ras-cross-talk-and-stoichiometric-deficiencies-are-determinants-of-sensitivity-to-targeted-therapies-in-krasg12r-pancreatic-ductal-adenocarcinoma","Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma","","Mutant and wild-type RAS cross-talk and KRAS allele–dependent signaling differences influence therapeutic responses in KRASG12R pancreatic ductal adenocarcinoma. Therapies targeting the RAF–MEK–ERK pathway usually show limited efficacy in KRAS-mutant disease, yet KRASG12R tumors demonstrate sensitivity to MEK inhibitors combined with autophagy inhibition. A systems-level analysis links this sensitivity to impaired activation of wild-type HRAS and NRAS due to weaker KRASG12R interactions with SOS and NF1, resulting in reduced MAPK signaling and greater MEKi response. Preclinical findings are supported clinically by hydroxychloroquine plus MEKi outcomes in KRASG12R metastatic PDAC, with a majority showing progression-free survival beyond 6 months and notable disease control.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mutant-and-wild-type-ras-cross-talk-and-stoichiometric-deficiencies-are-determinants-of-sensitivity-to-targeted-therapies-in-krasg12r-pancreatic-ductal-adenocarcinoma/354040/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mutant-and-wild-type-ras-cross-talk-and-stoichiometric-deficiencies-are-determinants-of-sensitivity-to-targeted-therapies-in-krasg12r-pancreatic-ductal-adenocarcinoma/354040.png","ImageObject",300,407,{"name":92,"@type":93},"Taylor Morgan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are RAF–MEK–ERK pathway inhibitors often less effective in KRAS-mutant cancers?","Question",{"text":112,"@type":113},"KRAS-driven pancreatic ductal adenocarcinomas are generally resistant to MEK inhibitors, limiting the effectiveness of RAF–MEK–ERK targeted therapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What mechanistic feature explains KRASG12R sensitivity to MEK inhibitors plus autophagy inhibition?",{"text":117,"@type":113},"KRASG12R has reduced ability to activate wild-type HRAS and NRAS due to weaker interactions with SOS and NF1, which leads to weaker holistic MAPK signaling and increased sensitivity to MEK inhibition.",{"name":119,"@type":110,"acceptedAnswer":120},"What clinical evidence supports combining MEK inhibitors with hydroxychloroquine in KRASG12R-mutated metastatic PDAC?",{"text":121,"@type":113},"In patients treated with MEKi plus hydroxychloroquine, five of eight (62.5%) had progression-free survival exceeding six months, and several patients showed disease control including stable disease and partial response with tumor size reduction.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354040,1790193274,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma  \nMandana Kamgar1, G. Aaron Hobbs2,3, Raven Davidson4, Daniel Dorbin4, Juliannie Herrera4,  \nJohn F. Langenheim5,6, Rachel A. Burge2, Mohammed Aldakkak7, Ryan D. Conrardy8, Aniko Szabo8, Sam Z. Thalji7, Bradley Mayer9, Justin J. Grahl9, Brian Y. Chung10, Alexandria Phan1, James P. Thomas1, Y. David Seo7, Douglas B. Evans7, Kathleen K. Christians7, Beth Erickson11, William A. Hall11, Ben George1, Susan Tsai12, Nikki K. Lytle7, Channing J. Der13, Razelle Kurzrock1, and Thomas McFall4,7  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Therapies targeting the RAF–MEK–ERK pathway are generally considered to have limited efficacy in KRAS-mutant cancers. However, specific KRAS mutants exhibit distinct behaviors. Notably, KRASG12R pancreatic ductal adenocarcinoma (PDAC) tumors have shown sensitivity to MEK inhibitors (MEKi) in combination with autophagy inhibitors, but a better understanding of the underlying mechanisms is needed to optimize this treatment strategy. Using a systems-level approach, we uncovered a mechanistic explanation for this phenomenon. Due to distinct biophysical properties, KRASG12R had an impaired ability to activate wild-type HRAS and NRAS (WT-RAS) compared with other KRAS mutants, such as KRASG12D. This reduced activation stemmed from the weaker interaction between KRASG12R and guanine exchange factors (SOS), as well asthe tumor suppressor neurofibromin (NF1), crucial in regulating WT-RAS activity. The impaired ability to activate WT-RASled to weaker holistic MAPK signaling in KRASG12R-driven tumors, which conferred increased sensitivity to MEKi. To substantiate the preclinical findings, the utility of MEKi in\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | combination with the autophagy inhibitor hydroxychloroquine was analyzed in patients with KRASG12R-mutated metastatic PDAC. Five of the eight (62.5%) patients treated in first- or second-line settings had a progression-free survival exceeding 6 months. Three patients had impressive disease control: two had stable disease of 11 and 22.7 months, and one achieved a partial response with an 83% decrease in tumor size that lasted for 8.9 months. Overall, this work highlights how systems-based approaches in precision medicine can uncover mechanistic insights to guide the identification of patients with PDAC most likely to benefit from tailored therapeutic strategies.\u003Cbr>Significance: The unique sensitivity of KRASG12R-mutant cancers to MEK inhibitors offers a critical advancement in understanding MAPK signaling and paving the way for precisiontargeted therapies in previously untreatable contexts.\u003Cbr>See related commentary by Tiriac and Engle, p. 1817 See related article by Burge et al., p. 1854\u003Cbr>See related article by Burge et al., p. 1868 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  ","cbCairbxOI8rwMUK","https://ap.wps.com/l/cbCairbxOI8rwMUK","pdf",9039778,18,"English","# Introduction\n## Precision oncology and KRAS alterations in PDAC\n## Background on MEK inhibitor resistance and KRAS-dependent sensitivity\n## Systems-level mechanistic rationale\n## Clinical substantiation with MEKi plus hydroxychloroquine","[{\"question\":\"Why are RAF–MEK–ERK pathway inhibitors often less effective in KRAS-mutant cancers?\",\"answer\":\"KRAS-driven pancreatic ductal adenocarcinomas are generally resistant to MEK inhibitors, limiting the effectiveness of RAF–MEK–ERK targeted therapy.\"},{\"question\":\"What mechanistic feature explains KRASG12R sensitivity to MEK inhibitors plus autophagy inhibition?\",\"answer\":\"KRASG12R has reduced ability to activate wild-type HRAS and NRAS due to weaker interactions with SOS and NF1, which leads to weaker holistic MAPK signaling and increased sensitivity to MEK inhibition.\"},{\"question\":\"What clinical evidence supports combining MEK inhibitors with hydroxychloroquine in KRASG12R-mutated metastatic PDAC?\",\"answer\":\"In patients treated with MEKi plus hydroxychloroquine, five of eight (62.5%) had progression-free survival exceeding six months, and several patients showed disease control including stable disease and partial response with tumor size reduction.\"}]","Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma | PDF",1790108551,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c2e118f87d8601f733f3dc7a403c885.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d79264a2516194fe6c8c841048112377.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/975daad3c516933525cc4e6ac36f86b3.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16305498715d19e50af7af140babae20.webp",980,1311]